NCT05724641 Arterial Spin Labeling MRI for Assessing Blood Perfusion in the Human Eye Repeatability Study and Clinical Application
| NCT ID | NCT05724641 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Cliniques universitaires Saint-Luc- Université Catholique de Louvain |
| Condition | Retinal Diseases |
| Study Type | INTERVENTIONAL |
| Enrollment | 70 participants |
| Start Date | 2023-01-10 |
| Primary Completion | 2026-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 70 participants in total. It began in 2023-01-10 with a primary completion date of 2026-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The MRI perfusion imaging using arterial spin labeling (ASL)'s non-invasive technique (i.e. without injection of contrast medium) allows, thanks to recent technological improvement of the spatial resolution, measuring several perfusion parameter of the retinal tissue such as the regional Blood Flow (rBF) or the cerebral blood flow (cBF) expressed in ml/100g/min. Reliable application of ASL thus requires the precision and specificity of the MRI protocol to be tested.
Eligibility Criteria
Inclusion criteria: * Carrier of target pathologies: TAO optic neuropathy, inflammatory optic neuropathy, ischemic optic neuropathy. * no cardiovascular risk factors or other ophthalmological pathology * adhere to the study protocol after reading the patient information document * signe the informed consent form to participate in the study * do not have any contraindications to an MRI examination Exclusion criteria * Usual contraindications to MRI (Pacemaker, Metallic foreign body, Cochlear implant,…) * Severe claustrophobia
Contact & Investigator
Idil Günes-Tatar, MD
PRINCIPAL INVESTIGATOR
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Frequently Asked Questions
Who can join the NCT05724641 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Retinal Diseases. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05724641 currently recruiting?
Yes, NCT05724641 is actively recruiting participants. Contact the research team at idil.gunes@saintluc.uclouvain.be for enrollment information.
Where is the NCT05724641 trial being conducted?
This trial is being conducted at Brussels, Belgium.
Who is sponsoring the NCT05724641 clinical trial?
NCT05724641 is sponsored by Cliniques universitaires Saint-Luc- Université Catholique de Louvain. The principal investigator is Idil Günes-Tatar, MD at Cliniques universitaires Saint-Luc- Université Catholique de Louvain. The trial plans to enroll 70 participants.